AbbVie raises 2024 profit outlook, reports strong Q1 sales for Skyrizi and Rinvoq
Humira maintained its blockbuster status and market share dominance in the first quarter of 2024, but experienced a drop in sales as biosimilar competition heated up, AbbVie reported on Friday.